Cancer experts at the Basser Center for BRCA in the Abramson Cancer Center of the University of Pennsylvania have announced a new collaboration with Tempus to improve and personalize treatment for patients with heritable BRCA mutations. Tempus, a technology company focused on helping doctors personalize cancer treatment will analyze the molecular and clinical data of patients who were treated at the Basser Center and harbor a BRCA mutation using machine learning and advanced bioinformatics.
Located within Penn Medicine’s Abramson Cancer Center, the Basser Center is focused solely on the prevention and treatment of cancers that are associated with heritable BRCA mutations. Men and women with a gene mutation in either BRCA1 or BRCA2 are at heightened risk for developing certain cancers, including breast, ovarian, prostate and pancreatic cancer.
As part of the initiative, Tempus will generate additional genomic and transcriptomic data for a subset of those patients. The goal is to help cancer specialists and research teams uncover novel patterns that will lead to better patient outcomes.
“The Basser Center is doing groundbreaking work aimed at saving the lives of men and women with heritable BRCA mutations. However, in order to accelerate the pace of discovery, we need to be able to understand why certain patients positively respond to treatment and others do not,” said Dr. Susan M. Domchek, Executive Director, Basser Center for BRCA in the Abramson Cancer Center of the University of Pennsylvania.